Bibliography
- Bhatt AP, Bhende PM, Sin SH, Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010;21(22):4455-63
- Chaisuparat R, Hu J, Jham BC, Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 2008;68(20):8361-8
- Sin SH, Roy D, Wang L, Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007;109(5):2165-73
- Wlodarski P, Kasprzycka M, Liu X, Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005;65(17):7800-8
- Majewski M, Korecka M, Kossev P, The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97(8):4285-90
- Stallone G, Schena A, Infante B, Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23
- Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77(5):760-2
- Lebbe C, Euvrard S, Barrou B, Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006;6(9):2164-8
- Boulanger E, Afonso PV, Yahiaoui Y, Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008;8(3):707-10
- El-Salem M, Raghunath PN, Marzec M, Activation of mTORC1 signaling pathway in AIDS-related lymphomas. Am J Pathol 2009;175(2):817-24
- Roy D, Dittmer DP. PTEN on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma. Am J Pathol 2011;179(4):2108-19
- Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001;98(1):136-41
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307(5712):1098-101
- Janes MR, Limon JJ, So L, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16(2):205-13
- Schenone S, Brullo C, Musumeci F, ATP-Competitive Inhibitors of mTOR: An Update. Curr Med Chem 2011;18(20):2995-3014
- Bhende PM, Park SI, Lim MS, The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010;24(10):1781-4
- Fan QW, Knight ZA, Goldenberg DD, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9(5):341-9
- Chiarini F, Fala F, Tazzari PL, Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69(8):3520-8
- Mazzoletti M, Bortolin F, Brunelli L, Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. Cancer Res 2011;71(13):4573-84
- Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 1998;273(7):3963-6
- Fan QW, Cheng C, Hackett C, Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010;3(147):ra81